Intellia Therapeutics CEO John Leonard has been experiencing a repeating cycle of positive trial data announcements followed by stock price declines. The market’s skepticism towards gene-editing companies like Intellia has raised doubts about the effectiveness of their CRISPR-based drugs compared to traditional medications. However, Intellia attempted to address these concerns by releasing new data from a year-long trial of its CRISPR drug for ATTR cardiomyopathy. The company aims to prove the efficacy of its innovative technology and differentiate itself from competitors. The article suggests that the success of Intellia’s trials will be crucial in restoring investor confidence in the company.
Source link
Intellia says CRISPR therapy showed gains in cardiomyopathy
